Vollure for the Correction of Atrophic Facial Scarring

Atrophic Scar Clinical Trial

— JVAS  

Official title:

Double Blind Split Face Randomized Placebo Controlled Clinical Trial Investigating Juvederm Vollure for the Correction of Atrophic Facial Scarring

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04519515
• Other study ID #: JVAS002
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 11, 2020
• Est. completion date: May 1, 2023

Study information

• Verified date: February 2021
• Source: Siperstein Dermatology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Subjects will be randomized to receive up to 1cc of Juvéderm Vollure on one side of their face and up to 1cc of Saline on the other. On Day 30, this treatment with the same left-right assignment can be repeated. Subjects will return 24-48 hours after their first treatment to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding short term adverse events. Subjects will fill out a 30 day subject diary and also return 30 and 90 days after their last treatment to fill out questionnaires, take pictures, complete the Global Aesthetic Improvement Scale (GAIS), and to be assessed on the QGSGS and for long-term adverse events by blinded evaluators. At 12 months, 18 months, and 24 months, the subjects will return to fill out questionnaires, take pictures, and to be assessed by blinded evaluators for long-term efficacy.

Description:

Subjects with grades ranging from 4-55 on the Quantitative Global Scarring Grading System (QGSGS)1 will be randomized to receive up to 1cc of Juvéderm Vollure on one side of their face and up to 1cc of Saline on the other. On Day 30, this treatment with the same left-right assignment can be repeated if optimal correction on the active intervention side has not been achieved according to the treating investigator. Subjects will return 24-48 hours after their first treatment to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding short term adverse events. Subjects will fill out a 30 day subject diary and also return 30 and 90 days after their last treatment to fill out questionnaires, take pictures, complete the Global Aesthetic Improvement Scale (GAIS), and to be assessed on the QGSGS and for long-term adverse events by blinded evaluators. The subjects will be eligible to receive treatment with Juvéderm Vollure 90 days after their last treatment on the placebo-controlled side if they choose. In addition, at 12 months, 18 months, and 24 months, the subjects will return to fill out questionnaires, take pictures, and to be assessed by blinded evaluators for long-term efficacy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: May 1, 2023
• Est. primary completion date: September 17, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years and older

Eligibility

Inclusion Criteria:

• In good general health as evidenced by medical history

• For females of reproductive potential: use of highly effective contraception and a negative urine pregnancy test at screening and all injection visits.

• Score of 4-55 on a validated scarring grading system

Exclusion Criteria:

• Subjects with allergies to hyaluronic acid filler, gram positive bacteria or lidocaine.

• Subjects with auto-immune conditions

• Subjects with diabetes

• Subjects with a history of sever anaphylactic reactions

• Subjects with cancer, or other life-threatening medical condition

• Subjects taking anti---coagulants, chemotherapy, immunosuppressive agents, immunomodulatory agents, diuretics, anti---histamines, or anti---inflammatory medications in the 2 weeks prior to the study or who will need to take these medications at any time during the first 120 days of the study.

• Subjects with any scheduled laser, light, or surgical procedures during the study, including dental surgery.

• Subjects who had neuromodulators in the past 6 months or hyaluronic acid fillers in the previous year on the face

• Subjects who at any time had surgery or more permanent fillers in the face such as Bellafill or Radiesse

• Subjects with tattoos or many skin growths on the face that would obscure visualization of the scars

• Subjects with a history of keloid or hypertrophic scar on the face

• Subjects unwilling or unable to sit still while an injector places Juvéderm Vollure in the face

• Subjects unwilling or unable to keep their head still during the photos

• Subjects who are pregnant or nursing

• Female subjects of child-bearing potential unable to take or use some form of birth control

• Subjects with any facial bruising or swelling

• Subjects with current skin infections, tumors, herpes outbreak or dermatitis on the face

• Subjects using skin-irritating topical preparations, pigmenting agents (self-tanning or bleaching creams), in the past two weeks or for the first 120 days of the study on the face

• Any medical condition that in the opinion of the Investigator would make the subject unsuitable for inclusion

• Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

• Study site personnel, close relatives of the study site personnel (e.g. parents, children, siblings, or spouse), employees, or close relatives of employee.

Related Conditions & MeSH terms

• Atrophic Scar
• Atrophy

Intervention

Device:
• Allergan Vollure
Injection of Allergan Vollure into Atrophic Scars

Locations

Country	Name	City	State
United States	Siperstein Dermatology Group	Boynton Beach	Florida

Sponsors (2)

Lead Sponsor	Collaborator
Siperstein Dermatology	Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantitiative Global Scaring Grading System (QGSGS) score	Difference in the mean QGSGS score from baseline to 90 days after injection in active group. The QGSGS score ranges from 0 to 84 and a higher score signifies a worse condition.	Baseline to 90 days after last injection
Secondary	Adverse Events	The difference in number of adverse events from control and active treatment group	Baseline to 90 days after last injection
Secondary	Global Aesthetic Improvement Scale (GAIS)	Difference in the mean GAIS score from baseline to 90 days after injection. The scale is a 5 point scale from -1 to 3. A higher score signifies more improvement, a negative score signifies worsening of the condition.	Baseline to 90 days after last injection
Secondary	24 Month Global Aesthetic Improvement Scale (GAIS) Results	Difference in the mean GAIS score from baseline to 24 months after injection. The scale is a 5 point scale from -1 to 3. A higher score signifies more improvement, a negative score signifies worsening of the condition.	24 months after 1st injection
Secondary	24 Month Quantitiative Global Scaring Grading System (QGSGS) Results	Difference in the mean QGSGS score from baseline to 24 months after injection. The QGSGS score ranges from 0 to 84 and a higher score signifies a worse condition.	24 months after 1st injection
Secondary	Result of Placebo Group based on the Quantitiative Global Scaring Grading System (QGSGS)	Difference in the mean QGSGS score from baseline to 90 days after injection of placebo group. The QGSGS score ranges from 0 to 84 and a higher score signifies a worse condition.	Baseline to 90 days after last injection